<DOC>
	<DOC>NCT00694720</DOC>
	<brief_summary>The primary objective of this study is to assess the activity on breathing parameters of 4 escalating doses of AVE0657 in comparison to placebo in patients with Cheynes-Stokes Breathing Syndrome.</brief_summary>
	<brief_title>Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Cheyne-Stokes Respiration</mesh_term>
	<criteria>Presence of Congestive heart failure (CHF) defined as ejection fraction ≤40% by history of echocardiography data and New York heart Association (NYHA) class IIIII and of typical cyclic crescendo and decrescendo change in breathing amplitude AHI ≥10 and &lt;60 and majority of the apneas to be ≥60% central in origin. Subject on supplemental oxygen The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Cheyne-stokes breathing</keyword>
</DOC>